Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.65 |
| ▸ | CNR1 | P21554 | 7/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 3/20 | 0.47 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568102 | 1.00 | CNR2 (0.65) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9893135 | 0.94 | CNR2 (0.58) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9893097 | 0.89 | CNR2 (0.72) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9893094 | 0.89 | CNR2 (0.72) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9893051 | 0.89 | CNR2 (0.72) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9892064 | 0.83 | CNR2 (0.71) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9893096 | 0.83 | CNR2 (0.65) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL13284768 | 0.80 | CNR2 (0.51) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL13284757 | 0.80 | CNR2 (0.51) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL13284553 | 0.80 | CNR2 (0.64) | CNR2CNR1CYP2C8CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885CYP2C8 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.